Affinity Asset Advisors, LLC Cogent Biosciences, Inc. Transaction History

Affinity Asset Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $501,999 - $775,000	-50,000 Reduced 25.9%	143,064 $1.54 Million
Q4 2022 Feb 13, 2023	BUY	$10.65 - $14.84 $415,105 - $578,418	38,977 Added 25.3%	193,064 $2.23 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $273,126 - $494,188	29,087 Added 23.27%	154,087 $2.3 Million
Q2 2022 Aug 12, 2022	BUY	$3.92 - $9.73 $490,000 - $1.22 Million	125,000 New	125,000 $1.13 Million

173

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $549M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.